FDA Approval of LYNPARZA® in US for HRR gene-mutated mCRPC
Josefa Briceno, M.D., Medical Head for the DNA Damage Response Franchise in US Medical Affairs at AstraZeneca discusses the recent FDA approval of LYNPA...
263 articles
Josefa Briceno, M.D., Medical Head for the DNA Damage Response Franchise in US Medical Affairs at AstraZeneca discusses the recent FDA approval of LYNPA...
Geoffrey Eubank, M.D., Medical Director of the Mid Ohio MS Center at OhioHealth Neurological Physicians, discusses 2 Phase lll clinical trials of Enspry...
Kathleen Hawker, M.D., Group Medical Director, Neuroscience at Genentech discusses the recent FDA approval of Enspryng™ (satralizumab-mwge) and the fi...
David Spetzler, President and Chief Scientific Officer at Caris Life Sciences® discusses the partnership with Elevation Oncology to identify patients f...
RJ Tesi, CEO of INmune Bio, Inc., a clinical stage immuno-oncology company targeting neuroinflammation to fight brain disease, discusses positive data p...
Bruce Boise, who worked in the pharmaceutical industry for over 20 years tells his story and discusses his new book "Cold Comfort: One man's struggle to...
Ayman Al-Hendy, MD, discusses the recent FDA approval of AbbVie’s ORIAHNN™ (elagolix, estradiol, and norethindrone acetate capsules; elagolix capsul...
Mark Erlander, CEO of Cardiff Oncology discusses their lead drug candidate Onvansertib and the three active clinical trials in colorectal cancer, acute ...
Vice President and Gastroenterology Disease Area Leader for the Immunology Therapeutic Area at Janssen Research & Development, LLC, talks about data fro...
Todd Norwood, Director of Clinical Services discusses Physera, a telehealth company that offers consumers/patients virtual physical therapy with license...